Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression

Objectives To use a data-driven approach to determine the existence and natural history of subtypes of Parkinson’s disease (PD) using two large independent cohorts of patients newly diagnosed with this condition. Methods 1601 and 944 patients with idiopathic PD, from Tracking Parkinson’s and Discovery cohorts, respectively, were evaluated in motor, cognitive and non-motor domains at the baseline assessment. Patients were recently diagnosed at entry (within 3.5 years of diagnosis) and were followed up every 18 months. We used a factor analysis followed by a k-means cluster analysis, while prognosis was measured using random slope and intercept models. Results We identified four clusters: (1)  fast motor progression with symmetrical motor disease, poor olfaction, cognition and postural hypotension; (2) mild motor and non-motor disease with intermediate motor progression; (3) severe motor disease, poor psychological well-being and  poor sleep with an intermediate motor progression; (4) slow motor progression with tremor-dominant, unilateral disease. Clusters were moderately to substantially stable across the two cohorts (kappa 0.58). Cluster 1 had the fastest motor progression in Tracking Parkinson’s at 3.2 (95% CI 2.8 to 3.6) UPDRS III points per year while cluster 4 had the slowest at 0.6 (0.1–1.1). In Tracking Parkinson’s, cluster 2 had the largest response to levodopa 36.3% and cluster 4 the lowest 28.8%. Conclusions We have found four novel clusters that replicated well across two independent early PD cohorts and were associated with levodopa response and motor progression rates. This has potential implications for better understanding disease pathophysiology and the relevance of patient stratification in future clinical trials.

[1]  B. Hayete,et al.  Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation , 2017, The Lancet Neurology.

[2]  A. Dagher,et al.  Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression , 2017, Brain : a journal of neurology.

[3]  A. Lang,et al.  Precision medicine for disease modification in Parkinson disease , 2017, Nature Reviews Neurology.

[4]  R. Barker,et al.  Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease , 2016, Parkinsonism & related disorders.

[5]  R. Barker,et al.  Tracking Parkinson’s: Study Design and Baseline Patient Data , 2015, Journal of Parkinson's disease.

[6]  Jean-François Gagnon,et al.  New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes. , 2015, JAMA neurology.

[7]  Y. Ben-Shlomo,et al.  Parkinson’s Disease Subtypes in the Oxford Parkinson Disease Centre (OPDC) Discovery Cohort , 2015, Journal of Parkinson's disease.

[8]  Giuseppe Orefice,et al.  The Heterogeneity of Early Parkinson’s Disease: A Cluster Analysis on Newly Diagnosed Untreated Patients , 2013, PloS one.

[9]  T. Robbins,et al.  The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  J. Nutt,et al.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.

[11]  T. Feng,et al.  Clinical heterogeneity in patients with early-stage Parkinson’s disease: a cluster analysis , 2011, Journal of Zhejiang University SCIENCE B.

[12]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes , 2011, The Lancet Neurology.

[13]  J. Marinus,et al.  Clinical subtypes of Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[14]  C. Clarke,et al.  Systematic review of levodopa dose equivalency reporting in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.

[15]  W. Heiser,et al.  The identification of Parkinson's disease subtypes using cluster analysis: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.

[16]  T Revesz,et al.  A clinico-pathological study of subtypes in Parkinson's disease. , 2009, Brain : a journal of neurology.

[17]  D. Aarsland,et al.  The association between motor subtypes and psychopathology in Parkinson's disease. , 2009, Parkinsonism & related disorders.

[18]  J. Speelman,et al.  Clinical heterogeneity in newly diagnosed Parkinson’s disease , 2008, Journal of Neurology.

[19]  Nicholas H. G. Holford,et al.  Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation , 2007, Pharmaceutical Research.

[20]  J. Nutt,et al.  Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[21]  T. Robbins,et al.  Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  J. Nutt,et al.  Modeling the Short- and Long-Duration Responses to Exogenous Levodopa and to Endogenous Levodopa Production in Parkinson's Disease , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[23]  G. Polesello,et al.  Clinical predictors in Parkinson's disease , 2002, Neurological Sciences.

[24]  H. Sagar,et al.  A data‐driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes , 1999, Movement disorders : official journal of the Movement Disorder Society.

[25]  Donald Hedeker,et al.  Application of random-efiects pattern-mixture models for miss-ing data in longitudinal studies , 1997 .

[26]  Y Mizuno,et al.  [Clinical subtypes of Parkinson's disease]. , 1993, No to shinkei = Brain and nerve.

[27]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[28]  Y. Ben-Shlomo,et al.  The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. , 2014, Parkinsonism & related disorders.

[29]  M. Vidailhet [Heterogeneity of Parkinson's disease]. , 2003, Bulletin de l'Academie nationale de medecine.